Pharmacokinetic (PK) and updated survival data from the Canadian cancer trials group IND226 study of durvalumab +/- tremelimumab in combination with platinum-doublet chemotherapy Conference Paper uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Additional Document Info
  •  
  • View All
  •  

authors

  • Hao, D
  • Ellis, PM
  • Laurie, SA
  • Juergens, Rosalyn
  • Mates, M
  • Bradbury, PA
  • Tsao, M
  • Tehfe, M
  • Kollmannsberger, CK
  • Goffin, John
  • Wheatley-Price, P
  • Hilton, J
  • Robinson, AG
  • Brown-Walker, P
  • Tu, D
  • Smoragiewicz, M
  • Seymour, LK

publication date

  • October 1, 2019